182 related articles for article (PubMed ID: 20360940)
1. The extracellular matrix glycoprotein elastin microfibril interface located protein 2: a dual role in the tumor microenvironment.
Mongiat M; Marastoni S; Ligresti G; Lorenzon E; Schiappacassi M; Perris R; Frustaci S; Colombatti A
Neoplasia; 2010 Apr; 12(4):294-304. PubMed ID: 20360940
[TBL] [Abstract][Full Text] [Related]
2. EMILIN2 down-modulates the Wnt signalling pathway and suppresses breast cancer cell growth and migration.
Marastoni S; Andreuzzi E; Paulitti A; Colladel R; Pellicani R; Todaro F; Schiavinato A; Bonaldo P; Colombatti A; Mongiat M
J Pathol; 2014 Mar; 232(4):391-404. PubMed ID: 24374807
[TBL] [Abstract][Full Text] [Related]
3. Regulation of the extrinsic apoptotic pathway by the extracellular matrix glycoprotein EMILIN2.
Mongiat M; Ligresti G; Marastoni S; Lorenzon E; Doliana R; Colombatti A
Mol Cell Biol; 2007 Oct; 27(20):7176-87. PubMed ID: 17698584
[TBL] [Abstract][Full Text] [Related]
4. Deregulated expression of Elastin Microfibril Interfacer 2 (EMILIN2) in gastric cancer affects tumor growth and angiogenesis.
Andreuzzi E; Fejza A; Capuano A; Poletto E; Pivetta E; Doliana R; Pellicani R; Favero A; Maiero S; Fornasarig M; Cannizzaro R; Iozzo RV; Spessotto P; Mongiat M
Matrix Biol Plus; 2020 May; 6-7():100029. PubMed ID: 33543026
[TBL] [Abstract][Full Text] [Related]
5. The ablation of the matricellular protein EMILIN2 causes defective vascularization due to impaired EGFR-dependent IL-8 production affecting tumor growth.
Paulitti A; Andreuzzi E; Bizzotto D; Pellicani R; Tarticchio G; Marastoni S; Pastrello C; Jurisica I; Ligresti G; Bucciotti F; Doliana R; Colladel R; Braghetta P; Poletto E; Di Silvestre A; Bressan G; Colombatti A; Bonaldo P; Mongiat M
Oncogene; 2018 Jun; 37(25):3399-3414. PubMed ID: 29483644
[TBL] [Abstract][Full Text] [Related]
6. Emilin2 fosters vascular stability by promoting pericyte recruitment.
Fejza A; Camicia L; Carobolante G; Poletto E; Paulitti A; Schinello G; Di Siena E; Cannizzaro R; Iozzo RV; Baldassarre G; Andreuzzi E; Spessotto P; Mongiat M
Matrix Biol; 2023 Sep; 122():18-32. PubMed ID: 37579864
[TBL] [Abstract][Full Text] [Related]
7. MULTIMERIN2 binds VEGF-A primarily via the carbohydrate chains exerting an angiostatic function and impairing tumor growth.
Colladel R; Pellicani R; Andreuzzi E; Paulitti A; Tarticchio G; Todaro F; Colombatti A; Mongiat M
Oncotarget; 2016 Jan; 7(2):2022-37. PubMed ID: 26655500
[TBL] [Abstract][Full Text] [Related]
8. EMILIN2 (Elastin microfibril interface located protein), potential modifier of thrombosis.
Sa Q; Hoover-Plow JL
Thromb J; 2011 May; 9():9. PubMed ID: 21569335
[TBL] [Abstract][Full Text] [Related]
9. Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss.
Rucci N; Capulli M; Ventura L; Angelucci A; Peruzzi B; Tillgren V; Muraca M; Heinegård D; Teti A
J Bone Miner Res; 2013 Sep; 28(9):1912-24. PubMed ID: 23559035
[TBL] [Abstract][Full Text] [Related]
10. Multiple-interactions among EMILIN1 and EMILIN2 N- and C-terminal domains.
Bot S; Andreuzzi E; Capuano A; Schiavinato A; Colombatti A; Doliana R
Matrix Biol; 2015 Jan; 41():44-55. PubMed ID: 25445627
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic and proapoptotic activity of a novel glycoprotein from U. indica is mediated by NF-kappaB and Caspase activated DNase in ascites tumor model.
Deepak AV; Salimath BP
Biochimie; 2006; 88(3-4):297-307. PubMed ID: 16216405
[TBL] [Abstract][Full Text] [Related]
12. EMILIN2 regulates platelet activation, thrombus formation, and clot retraction.
Huang M; Sannaningaiah D; Zhao N; Gong Y; Grondolsky J; Hoover-Plow J
PLoS One; 2015; 10(2):e0115284. PubMed ID: 25658937
[TBL] [Abstract][Full Text] [Related]
13. 19-peptide, a fragment of tumstatin, inhibits the growth of poorly differentiated gastric carcinoma cells in vitro and in vivo.
He Y; Jiang Y; Li YJ; Liu XH; Zhang L; Liu LJ; Shi H; Li HN; Ma YC; Jin XM
J Gastroenterol Hepatol; 2010 May; 25(5):935-41. PubMed ID: 20546447
[TBL] [Abstract][Full Text] [Related]
14. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy of Anti-PD-L1 Treatment in Melanoma Is Associated with the Expression of the ECM Molecule EMILIN2.
Fejza A; Polano M; Camicia L; Poletto E; Carobolante G; Toffoli G; Mongiat M; Andreuzzi E
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299131
[TBL] [Abstract][Full Text] [Related]
17. Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis.
Choi SH; Lee JY; Suh JS; Park YS; Chung CP; Park YJ
Int J Nanomedicine; 2016; 11():4643-4656. PubMed ID: 27695323
[TBL] [Abstract][Full Text] [Related]
18. Tumor targeting and microenvironment-responsive multifunctional fusion protein for pro-apoptotic peptide delivery.
Yin J; Liu D; Bao L; Wang Q; Chen Y; Hou S; Yue Y; Yao W; Gao X
Cancer Lett; 2019 Jun; 452():38-50. PubMed ID: 30904618
[TBL] [Abstract][Full Text] [Related]
19. EMILINs interact with anthrax protective antigen and inhibit toxin action in vitro.
Doliana R; Veljkovic V; Prljic J; Veljkovic N; De Lorenzo E; Mongiat M; Ligresti G; Marastoni S; Colombatti A
Matrix Biol; 2008 Mar; 27(2):96-106. PubMed ID: 17988845
[TBL] [Abstract][Full Text] [Related]
20. Active sites of human MEPE-ASARM regulating bone matrix mineralization.
Minamizaki T; Sakurai K; Hayashi I; Toshishige M; Yoshioka H; Kozai K; Yoshiko Y
Mol Cell Endocrinol; 2020 Nov; 517():110931. PubMed ID: 32712387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
